Skip to main content
. 2021 Oct 21;12(1):8100–8115. doi: 10.1080/21655979.2021.1985259

Figure 4.

Figure 4.

LINC00958 interacted with miR-3064-5p in colorectal cancer cells

(a) StarBase analysis showed the predicted binding sequences of miR-3064-5p for LINC00958. (b) Dual luciferase assay was performed in cells co-transfected with plasmids LINC00958-WT or LINC00958-MUT1 or MUT2 and NC mimics or miR-3064-5p mimic in HCT116 and HCT8 cells. (c) The enrichment of LINC00958 by treating with miR-3064-5p mimic in HCT116 and HCT8 cells through RIP assay. (d) Correlation analysis between miR-3064-5p expression and LINC00958 expression. (e) RT-qPCR detection of miR-3064-5p expression in colorectal cancer cells (HCT116 and HCT8 cells) and normal FHC cells. (f) RT-qPCR detection of miR-3064-5p and LINC00958 expression in HCT116 and HCT8 cells transfected with NC, Si-LINC00958, miR-3064-5p inhibitor, and Si-LINC00958+ miR-3064-5p inhibitor. *, P < 0.05; **, P < 0.001 compared with blank. #, P < 0.05; ##, P < 0.001 compared with Si-LINC00958+ miR-3064-5p inhibitor. NC, negative control; WT, wild-type; MUT, Mutant; Si-LINC00958, SiRNA-LINC00958; Si-LINC00958+ miR-3064-5p inhibitor, SiRNA-LINC00958+ miR-3064-5p inhibitor.